AU2011343739A1 - Treatment of spinal cord injury and traumatic brain injury using placental stem cells - Google Patents

Treatment of spinal cord injury and traumatic brain injury using placental stem cells Download PDF

Info

Publication number
AU2011343739A1
AU2011343739A1 AU2011343739A AU2011343739A AU2011343739A1 AU 2011343739 A1 AU2011343739 A1 AU 2011343739A1 AU 2011343739 A AU2011343739 A AU 2011343739A AU 2011343739 A AU2011343739 A AU 2011343739A AU 2011343739 A1 AU2011343739 A1 AU 2011343739A1
Authority
AU
Australia
Prior art keywords
cells
placental
stem cells
isolated
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011343739A
Other languages
English (en)
Inventor
Stewart Abbot
James W. Edinger
Aleksandar Francki
Vladimir Jankovic
Aleksandr Kaplunovsky
Kristen Labazzo
Bitao Laing
Eric Law
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clarity Acquisition II LLC
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of AU2011343739A1 publication Critical patent/AU2011343739A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
AU2011343739A 2010-12-17 2011-12-15 Treatment of spinal cord injury and traumatic brain injury using placental stem cells Abandoned AU2011343739A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424559P 2010-12-17 2010-12-17
US61/424,559 2010-12-17
PCT/US2011/065170 WO2012083024A1 (en) 2010-12-17 2011-12-15 Treatment of spinal cord injury and traumatic brain injury using placental stem cells

Publications (1)

Publication Number Publication Date
AU2011343739A1 true AU2011343739A1 (en) 2013-05-02

Family

ID=46234728

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011343739A Abandoned AU2011343739A1 (en) 2010-12-17 2011-12-15 Treatment of spinal cord injury and traumatic brain injury using placental stem cells

Country Status (9)

Country Link
US (1) US20120156230A1 (enExample)
EP (1) EP2651451A4 (enExample)
JP (1) JP2014507390A (enExample)
KR (7) KR20200116546A (enExample)
CN (1) CN103501822A (enExample)
AU (1) AU2011343739A1 (enExample)
CA (1) CA2821818A1 (enExample)
MX (1) MX2013006595A (enExample)
WO (1) WO2012083024A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6204976B2 (ja) * 2012-05-16 2017-09-27 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 多能性幹細胞由来の細胞培養物からニューロンを単離するための細胞表面特性
JP2015521630A (ja) * 2012-06-26 2015-07-30 ラスティー プロパティー ホールディングス プロプライエタリー リミテッド 頭痛の頻度および／または重症度を下げるための組成物および方法
WO2014022427A1 (en) * 2012-08-02 2014-02-06 Bioaxone Biosciences Inc. Inhibition of rho and or rock and cell transplantation
EP2994147A4 (en) * 2013-05-10 2017-03-08 Cell-Innovations IP Pty Ltd Compositions and methods for the treatment of tinnitus
WO2015023901A1 (en) * 2013-08-15 2015-02-19 The Regents Of The University Of California Placenta-derived multipotent stem cells
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
US10493105B2 (en) * 2014-09-11 2019-12-03 Taiwan Mitochondrion Applied Technology Co., Ltd Isolated adipose-derived mesenchymal stem cells treated with angelica extract or butylidenephthalide, and wherein the cells have an increased mitochondrial membrane potential and a decreased level of IL-8, and methods for treating parkinson's disease
GB201518263D0 (en) * 2015-10-15 2015-12-02 Oxford Bioelectronics Ltd Method
EP3423070B1 (en) * 2016-03-03 2022-05-04 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
EA201991371A1 (ru) * 2016-12-05 2019-12-30 Селулэрити, Инк. Лечение лимфедемы и связанных состояний с использованием плацентарных адгезивных клеток
WO2018198012A1 (en) * 2017-04-24 2018-11-01 Pluristem Ltd. Methods and compositions for treating neurological disorders
US20180322956A1 (en) * 2017-05-05 2018-11-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Time Window-Based Platform for the Rapid Stratification of Blunt Trauma Patients into Distinct Outcome Cohorts
WO2018222723A1 (en) 2017-05-30 2018-12-06 Vertex Pharmaceuticals Incorporated C3 fusion protein and methods of making and using thereof
CN107227521B (zh) * 2017-08-09 2023-03-14 青岛金汇丰机械有限公司 一种五轴毛纺粗纱机
KR20190048894A (ko) 2017-10-31 2019-05-09 경상대학교산학협력단 Jnk 활성 억제제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
CN108413478A (zh) * 2018-02-11 2018-08-17 广东美的环境电器制造有限公司 一种控制方法、装置及计算机可读存储介质
KR102070403B1 (ko) 2019-09-06 2020-01-28 경상대학교 산학협력단 Jnk 활성 억제제를 유효성분으로 포함하는 외상성 뇌손상의 치료용 약학적 조성물
CN114561355B (zh) * 2022-01-23 2023-04-11 四川大学华西医院 一种脊髓瘢痕组织细胞急性快速分离方法
CN117274869B (zh) * 2023-09-25 2024-03-26 北方工业大学 一种基于形变场提取的细胞形变动态分类方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
KR20180105266A (ko) * 2005-12-29 2018-09-27 안트로제네시스 코포레이션 태반 줄기 세포 집단
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
CN103356710A (zh) * 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
US20090214484A1 (en) * 2008-02-22 2009-08-27 Nikolay Mironov Stem cell therapy for the treatment of central nervous system disorders
CA2734237C (en) * 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
WO2010059828A1 (en) * 2008-11-19 2010-05-27 Anthrogenesis Corporation Amnion derived adherent cells

Also Published As

Publication number Publication date
WO2012083024A1 (en) 2012-06-21
KR20230116964A (ko) 2023-08-04
KR20130128437A (ko) 2013-11-26
MX2013006595A (es) 2014-04-07
KR20200116546A (ko) 2020-10-12
KR20180100251A (ko) 2018-09-07
JP2014507390A (ja) 2014-03-27
KR20190090882A (ko) 2019-08-02
KR20210107144A (ko) 2021-08-31
CA2821818A1 (en) 2012-06-21
CN103501822A (zh) 2014-01-08
US20120156230A1 (en) 2012-06-21
KR20220103812A (ko) 2022-07-22
EP2651451A1 (en) 2013-10-23
EP2651451A4 (en) 2014-05-21
WO2012083024A8 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
US20120156230A1 (en) Treatment of spinal cord injury and traumatic brain injury using placental stem cells
US11090339B2 (en) Treatment of pain using placental stem cells
US8071376B2 (en) Production of oligodendrocytes from placenta-derived stem cells
EP3031909B1 (en) Immunomodulation using placental stem cells
US20120201787A1 (en) Treatment of spinal cord injury and traumatic brain injury using amnion derived adherent cells
HK40005664A (en) Treatment of pain using placental stem cells
HK1192729A (en) Treatment of pain using placental stem cells
HK1162600A (en) Production of oligodendrocytes from placenta-derived stem cells
HK1192729B (en) Treatment of pain using placental stem cells

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application